ACADIA Pharmaceuticals Inc. ACAD Securities Lawsuit

Company:	ACADIA Pharmaceuticals Inc.
Ticker Symbol:	ACAD
Class Period:	Feb-26-15 to Mar-11-15
Date Filed:	Mar-16-15
Lead Plaintiff Deadline:	May-15-15
Court:	Southern District of California
Allegations:

Los Angeles, CA: A securities class action lawsuit has been filed against ACADIA Pharmaceuticals Inc. ACAD, on behalf of investors who purchased the Company's securities between February 26, 2015 and March 11, 2015, inclusive (the "Class Period"). This action is pending in the United States District Court for the Southern District of California.

ACADIA and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws. On February 26, 2015, ACADIA announced its 2014 fourth quarter and year-end financial results and told investors that it "remain[ed] on track to submit [its] New Drug Application to the FDA in the first quarter of 2015."

Then, on March 11, 2015, ACADIA issued a press release announcing a change in the timing of its planned NDA submission to the FDA for its drug NUPLAZID from the first quarter of 2015 to the second half of 2015. In a separate press release the same day, ACADIA announced the retirement of the Company's Chief Executive Officer and director, Uli Hacksell. On this news, the price of ACADIA's shares plummeted by 22%.

If you acquired the securities of the defendants during the Class Period you may, no later than the Lead Plaintiff Deadline shown above, request that the Court appoint you as lead plaintiff through counsel of your choice. You may also choose to remain an absent class member. A lead plaintiff must meet certain requirements.

ACADIA Pharmaceuticals Inc. ACAD Securities Fraud Legal Help

If you have suffered from financial losses, you may qualify for damages or remedies that may be awarded in a possible ACADIA Pharmaceuticals Inc. securities class action lawsuit. Please click the link below to submit your complaint for a free evaluation.